echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > How to choose the TCR-Seq method? An in-depth evaluation of a 54-point SCI article is worthy of attention!

    How to choose the TCR-Seq method? An in-depth evaluation of a 54-point SCI article is worthy of attention!

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Perhaps you have also noticed that in recent years, more and more scientific researchers at home and abroad have devoted themselves to the research camp of immune repertoire


    Among many TCR research methods, NGS technology has gradually become the mainstream analysis method of TCR


    Related background of TCR-Seq

    ▪ Starting material DNA or RNA?

    Most TCR-Seq methods can be roughly divided into DNA-based methods and RNA-based methods based on the starting material


    ▪ Database construction strategy

    Two commonly used methods are mPCR (multiplex PCR) and 5'RACE (Rapid Amplification of cDNA Ends)


    mPCR supports DNA and RNA initiation and usually includes two rounds of PCR


    Literature interpretation

    Four key factors need to be considered when choosing a TCR-Seq method: reproducibility, repeatability, sensitivity and specificity


    Analyze the repeatability and reproducibility of different TCR-Seq methods

    The research team compared the repeatability (ie, the similarity between data obtained by different samples using the same method) and reproducibility (ie, the similarity between data obtained by different methods) of different TCR-Seq


    Analyze the sensitivity and specificity of different TCR-Seq methods

    The next evaluation is for sensitivity and specificity


    The dataset generated by RACE-3 contains up to 50% of TRA and up to 40% of TRB MRCs, compared with 10-20% of other RACE methods (Figure 5, Panel A in the literature)


    in conclusion

    In these TCR-Seq methods, the diversity and detection of rare clones are highly dependent on the type and quantity of starting materials



    Editor's summary:

    Although the Eugster team’s method was considered to be the most reproducible method for TRA analysis in the final analysis, the sensitivity of the SMARTer Human TCR a/b Profiling Kit is comparable to the Eugster team’s method and company A’s platform


    Takara Bio has always been committed to providing our customers with high-quality and innovative products



    SMARTer Human TCR a/b Profiling Kit v2 (TCRv2)

    • Support 10 ng-1 μg total RNA derived from peripheral blood lymphocytes or 1 ng-100 ng T cells, as well as complete 1,000-10,000 T cells after purification;




    I hope that the content shared in this issue can help you choose a suitable TCR-Seq library construction plan!

    references

    1.


    Extended reading: 50 20-point articles, netizens: Immune repertoire analysis should be popular? !

    For more details, please click:
    Takara Bio China official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.